Wikipedia:Version 1.0 Editorial Team/Pharmacology articles by quality log

This is a log of operations by a bot. The contents of this page are unlikely to need human editing. In particular, links should not be disambiguated as this is a historical record.

July 14, 2024

Assessed

Aspoxicillin (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
Disitamab vedotin (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)

July 13, 2024

Reassessed

Latanoprostene bunod (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
Pixantrone (talk) reassessed. Importance rating changed from Low-Class to Mid-Class. (rev · t)

Assessed

Drug antagonism (talk) assessed. Quality assessed as B-Class. (rev · t) Importance assessed as Unknown-Class. (rev · t)

July 12, 2024

Renamed

Trevena Inc renamed to Trevena, Inc..

Reassessed

CI-966 (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
CI-988 (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
Exisulind (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)

Assessed

Trevena, Inc. (talk) assessed. Quality assessed as NA-Class. (rev · t) Importance assessed as Low-Class. (rev · t)

July 11, 2024

Reassessed

3D printed medication (talk) reassessed. Quality rating changed from NA-Class to C-Class. (rev · t)

July 10, 2024

Reassessed

Halcinonide (talk) reassessed. Importance rating changed from Unknown-Class to Mid-Class. (rev · t)

Assessed

Draft:Super-pharma-fr (talk) assessed. Importance assessed as NA-Class. (rev · t)

July 9, 2024

Reassessed

Deprenyl (talk) reassessed. Quality rating changed from Unassessed-Class to Start-Class. (rev · t)
Sofosbuvir/velpatasvir/voxilaprevir (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
Vorinostat (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)

Assessed

Dapagliflozin/sitagliptin (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Mid-Class. (rev · t)

July 8, 2024

Assessed

Licogliflozin (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
Mizagliflozin (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
Rongliflozin (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)